Infarct size limitation has been a therapeutic aim for many years, particularly in view of the known close relationship between the extent of myocardial damage occurring at the time of the infarction, and future morbidity and mortality. It is only in the last decade, however, since the pathophysiology of myocardial infarction has been better understood, that this aim has become a clinical reality. Thus, it is now well established that myocardial infarction is caused by intracoronary thrombosis, usually at the site of a ruptured atheromatous plaque,' and this occlusive thrombus can be dissolved by the administration of intracoronary or intravenous thrombolytic agents. [4] [5] [6] Although this clinical breakthrough has come in the last 10 years, the pioneering work on this subject was in fact performed in the late 1950s and early 1960s, using open chested anaesthetized dogs to study the effects of reperfusion on ischaemic myocardium.7-1' The results of these early studies demonstrated the experimental basis for the theory that ischaemic cell death has an early reversible and later irreversible phase. However, it was not until the late 1970s that a full analysis of the timing of cell death was complete and a time frame for intervention to reduce infarct size established. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Reimer and Jennings,14 in a classical paper, were at this time able to produce, from animal studies, a plot of the percentage of myocardium salvageable (by reperfusion) against duration of occlusion of a coronary artery. This work clearly demonstrated a therapeutic time window in which intervention was able to modify infarct size and it was from this paper, together with work showing the role of occlusive thrombus resulting in myocardial infarction,1 3 that a number of clinical studies on infarct size limitation were moulded.
Infarct size limitation has been a therapeutic aim for many years, particularly in view of the known close relationship between the extent of myocardial damage occurring at the time of the infarction, and future morbidity and mortality. It is only in the last decade, however, since the pathophysiology of myocardial infarction has been better understood, that this aim has become a clinical reality. Thus, it is now well established that myocardial infarction is caused by intracoronary thrombosis, usually at the site of a ruptured atheromatous plaque,' and this occlusive thrombus can be dissolved by the administration of intracoronary or intravenous thrombolytic agents. [4] [5] [6] Although this clinical breakthrough has come in the last 10 Initial human work on this subject in the early 1980s was largely confined to the administration of intracoronary streptokinase4'6,'1516 and it therefore required that medical practitioners involved in the work had access to a cardiac catheterization laboratory. In these studies, intracoronary streptokinase was infused into the occluded coronary artery at a standard rate, and patency rates achieved were in the region of 70-80% after 20-30 minutes perfusion. It was realized early on however that the assessment of success in restoring coronary patency was complicated by the phenomenon of spontaneous reperfusion. 17, 18 However, in the many studies performed at this time, coronary patency rates were consistently significantly higher after the administration of thrombolytic therapy than in patients treated conventionally.
Because of logistic problems with intracoronary infusions the obvious next development for thrombolytic therapy was the utilization of the intravenous route of administration. Streptokinase given in this way achieved a slightly reduced patency rate (55-75%) as compared to intracoronary streptokinase'9'20 but it was clear that if treatment was given to patients in the critical first few hours after infarction then limitation of infarct size was possible. 6 The most popular regimen used for the administration of intravenous streptokinase was that developed by Schroder et al.5 based on the earlier work of Breddin21; using this regime, one and a half million units of streptokinase are given by slow intravenous infusion over 60 minutes.
Following the administration of either intracoronary or intravenous streptokinase it became clear that reperfusion could be established in between 55% and 80% of cases but the next obvious question to be posed was whether this reperfusion had any impact on patient survival and ventricular function. Unfortunately all of the early studies were too small to answer these questions but a pooled assessment of these studies by Yusufl6 suggested that there was an increase in survival of 10-15% and a significant improvement in global and regional left ventricular function following reperfusion. The first large study to clearly outline the true benefit of this therapy, however, was the GISSI study.22 In this study 31 ,826 patients were screened for entry and 11,806 patients randomized to receive either placebo or one and a half million units of streptokinase infused intravenously over one hour. Short term (3 weeks) mortality was 13% in placebo group and 10.7% in treated group (P<0.02), a total reduction in mortality of 17%. Subgroup analysis revealed more interesting findings in that the greatest improvement in survival occurred in those patients treated within 3 hours of infarction (mortality 9.2% vs 12%). In the small number of patients treated in the first hour following onset of pain (1000 patients) mortality was 8.2% in the treated group and 15.4% in the untreated group, a 46% improvement in the chances of survival. The late results of the GISSI study have now been published23 and this improvement in early mortality persists to one year.
The importance of early treatment was echoed by the results of another study reported by the Netherlands Interuniversity Group,24'25 who demonstrated a reduction in infarct size of 51% in patients treated within one hour of onset of symptoms, 31% in those treated within 1-2 hours and 13% in those treated between 2-4 hours. In this study, improvement in global left ventricular function was also documented in all groups but this was greatest in those patients treated early.
Both the GISSI study and the Netherlands Interuniversity study looked also at the relative benefits for thrombolytic therapy for anterior and inferior infarctions. The clear message to emerge was that although inferior infarcts may obtain some benefit, particularly if treated in the first 2 hours after onset of symptoms, it is the patients with anterior infarction who benefit most in terms of both improvement in left ventricular ejection fraction and improvement in survival.
In the last few weeks, results of the Oxford based ISIS 2 study have been published.* In this study, as in the GISSI study and the Netherlands Interuniversity study, intravenous streptokinase produced a significant reduction in early mortality after myocardial infarction; this reduction could be enhanced by the simultaneous administration of oral aspirin. APSAC is also theoretically more specific than streptokinase for fibrin bound in clot and has the advantage over other agents that it can be given as a single intravenous injection over 5 minutes. An interim analysis of 1004 patients entered into a control trial of this agent30 has recently been published showing a significant reduction in mortality over 30 days (32/502 patient deaths given APSAC; 61/502 patient deaths given placebo); the preliminary data suggests continuation of benefit to one year.
At present, however, we are not in a position to say which agent-streptokinase, tPA or APSACis best, as theoretical benefits have not been borne out in clinical practice. It seems unlikely until large cooperative studies have been carried out that a consensus on a single ideal agent will emerge.
Management after thrombolysis
Re-thrombosis of the atherosclerotic coronary artery might be expected to occur after thrombolysis unless this procedure was followed by either the administration of anticoagulants or antiplatelet drugs or by the performance of a technique such as coronary angioplasty, since about 70% of reperfused vessels are left with significant coronary artery stenosis at the site of initial occlusion.31 '32 
